Tag Archives: Sutent

New Hope for Patients with Advanced Metastatic Colorectal Cancer Patients

Posted on March 11, 2012 by wngai

Colorectal cancer is the fourth most common cancer in men and women with nearly 500,000 deaths due to colorectal cancer every year. When detected early at localized stage I, the 5-year survival rate can reach 90%. At this stage, surgical … Continue reading →

Posted in Cancer, Colorectal cancer | Tagged 5-Fluorouracil, Avastin, bevacizumab, camptosar, Cetuximab, Eloxatin, Erbitux, gastrointestinal stromal tumors, GIST, Gleevec, imatanib, Irinotecan, leucovorin, metastatic colorectal cancer, oxaliplatin, regoragenib, sunitinib, Survival, Sutent | Comments Off

FDA Approved Afinitor for a Type of Advanced Pancreatic Cancer

Posted on May 30, 2011 by wngai

The US Food and Drug Administration (FDA) has approved everolimus (Afinitor) to treat patients with advanced pancreatic neuroendocrine tumors (pNETs). pNETs is a rare, slow-growing form of pancreatic cancer. In theUnited States, there are fewer than 1000 new pNET cases … Continue reading →

Posted in Cancer, Pancreatic Cancer | Tagged advanced renal cell carcinoma, Afinitor, Everolimus, FDA, mTOR, Nexavar, pancreatic neuroendocrine tumors, pNETs, RADIAN-3, sorafenib, subependymal giant cell astrocytoma, sunitinib, Sutent, tuberous sclerosis | Comments Off

Europe Approved Sutent for Rare Pancreatic Cancer

Posted on December 22, 2010 by wngai

The European Commission has recently approved Sutent (sunitinib) as a medicine for treating patients with pancreatic neuroendocrine tumors (NET). The drug is now indicated to treat unresectable metastatic, well-differentiated pancreatic NET in adults with disease progression. The approval was based … Continue reading →

Posted in Cancer, Pancreatic Cancer | Tagged metastatic, Pancreatic Cancer, pancreatic neuroendocrine tumors, progression-free survival, sunitinib, Sutent | Comments Off

Everolimus (Affinitor) Improves Survival in Pancreatic Neuroendocrine Tumors

Posted on July 25, 2010 by wngai

Pancreatic neuroendocrine tumors affect the hormone-producing tissues within the pancreas, and have an incidence rate, affecting only 2 to 4 people per million worldwide. The incidence, however, is rising, and has quadrupled in the past 30 years, according to data … Continue reading →

Posted in Cancer, Pancreatic Cancer | Tagged Affinitor, anthracyclines, Everolimus, fluoropyrimidines, Neuroendocrine tumor, octreotide, Pancreatic Cancer, Sandostatin, streptozocin, sunitinib, Survival, Sutent, Zanosar | Comments Off

Tag Archives: Sutent

New Hope for Patients with Advanced Metastatic Colorectal Cancer Patients

FDA Approved Afinitor for a Type of Advanced Pancreatic Cancer

Europe Approved Sutent for Rare Pancreatic Cancer

Everolimus (Affinitor) Improves Survival in Pancreatic Neuroendocrine Tumors

Product Reviews

Categories

Archives

Subscribe to Healthreason